Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKLINASDAQ:AVRNYSE:INFUNASDAQ:LUCD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/AAVRAnteris Technologies Global$3.48-8.4%$4.25$2.34▼$8.79$137.04MN/A293,471 shs332,630 shsINFUInfuSystem$6.25+1.5%$5.80$4.61▼$9.97$131.35M1.81115,683 shs171,427 shsLUCDLucid Diagnostics$1.04+1.0%$1.26$0.72▼$1.80$111.43M1.23671,020 shs1.38 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%0.00%AVRAnteris Technologies Global0.00%-6.40%-19.83%+31.03%+379,999,900.00%INFUInfuSystem0.00%+0.65%+0.82%+23.20%-9.81%LUCDLucid Diagnostics0.00%-7.18%-15.81%-29.94%+37.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKLIAkiliN/AN/AN/AN/AN/AN/AN/AN/AAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AN/AN/AN/AINFUInfuSystem1.8831 of 5 stars2.02.00.00.00.04.21.9LUCDLucid Diagnostics2.132 of 5 stars3.63.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKLIAkili 0.00N/AN/AN/AAVRAnteris Technologies Global 3.00Buy$16.50374.14% UpsideINFUInfuSystem 4.00Strong Buy$13.00108.00% UpsideLUCDLucid Diagnostics 3.20Buy$3.55241.35% UpsideCurrent Analyst Ratings BreakdownLatest AKLI, AVR, LUCD, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.50 ➝ $7.755/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKLIAkili$1.95M17.46N/AN/A$0.75 per share0.58AVRAnteris Technologies Global$2.70M46.48N/AN/A$1.74 per share2.00INFUInfuSystem$137.58M0.95$0.49 per share12.79$2.47 per share2.53LUCDLucid Diagnostics$4.35M25.87N/AN/A($0.78) per share-1.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKLIAkili-$59.49M-$0.61N/AN/AN/A-2,492.04%-79.93%-59.16%N/AAVRAnteris Technologies Global-$76.29MN/A0.00N/AN/AN/AN/AN/AN/AINFUInfuSystem$870K$0.14104.1820.16N/A1.12%2.78%1.41%N/ALUCDLucid Diagnostics-$45.53M-$1.34N/AN/AN/A-1,699.86%N/A-124.27%8/11/2025 (Estimated)Latest AKLI, AVR, LUCD, and INFU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025AVRAnteris Technologies GlobalN/A-$0.61N/A-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKLIAkiliN/AN/AN/AN/AN/AAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKLIAkili0.085.805.80AVRAnteris Technologies GlobalN/A3.673.65INFUInfuSystem0.501.981.59LUCDLucid DiagnosticsN/A0.750.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKLIAkili53.12%AVRAnteris Technologies GlobalN/AINFUInfuSystem71.13%LUCDLucid Diagnostics74.01%Insider OwnershipCompanyInsider OwnershipAKLIAkili10.10%AVRAnteris Technologies GlobalN/AINFUInfuSystem11.40%LUCDLucid Diagnostics6.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKLIAkili13078.73 million70.78 millionOptionableAVRAnteris Technologies Global13836.06 millionN/AN/AINFUInfuSystem41021.02 million19.10 millionOptionableLUCDLucid Diagnostics70108.19 million100.83 millionNo DataAKLI, AVR, LUCD, and INFU HeadlinesRecent News About These CompaniesMajor California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA TestJune 18, 2025 | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 39.3% in MayJune 16, 2025 | marketbeat.comLucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Rating of "Buy" by BrokeragesJune 16, 2025 | marketbeat.comLucid Diagnostics to Join Russell 2000® and Russell 3000® IndexesMay 27, 2025 | prnewswire.comLucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potentialMay 21, 2025 | investing.comLucid Diagnostics Reports Increased Losses Amid Revenue DeclineMay 15, 2025 | tipranks.comEarnings call transcript: Lucid Diagnostics Q1 2025 highlights growth and strategic expansionMay 15, 2025 | investing.comPAVmed Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | prnewswire.comLucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call TranscriptMay 14, 2025 | seekingalpha.comLucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue EstimatesMay 14, 2025 | zacks.comLucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comWill Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should KnowMay 7, 2025 | zacks.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025April 30, 2025 | prnewswire.comLucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in studyApril 26, 2025 | markets.businessinsider.comLucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic PatientsApril 24, 2025 | theglobeandmail.comLucid reports encouraging results from EsoGuard studyApril 24, 2025 | msn.comNCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERDApril 24, 2025 | prnewswire.comLucid Diagnostics price target raised to $7.50 from $7 at AscendiantApril 22, 2025 | markets.businessinsider.comLucid Diagnostics Closes $16.1 Million Public OfferingApril 11, 2025 | tipranks.comLucid Diagnostics Announces Closing of Public Offering of Common StockApril 11, 2025 | prnewswire.comLucid Diagnostics 12.5M share Spot Secondary priced at $1.20April 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKLI, AVR, LUCD, and INFU Company DescriptionsAkili NASDAQ:AKLIAkili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.Anteris Technologies Global NASDAQ:AVR$3.48 -0.32 (-8.42%) As of 04:00 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.InfuSystem NYSE:INFU$6.25 +0.09 (+1.46%) As of 04:00 PM EasternInfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Lucid Diagnostics NASDAQ:LUCD$1.04 +0.01 (+0.97%) Closing price 04:00 PM EasternExtended Trading$1.07 +0.03 (+2.88%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
